Enhanced Delivery and Bioactivity of the Neurturin Neurotrophic Factor through Focused Ultrasound—Mediated Blood—Brain Barrier Opening in vivo
暂无分享,去创建一个
Elisa E Konofagou | Shutao Wang | E. Konofagou | Gesthimani Samiotaki | Shutao Wang | Camilo Acosta | C. Acosta | G. Samiotaki
[1] Jameel A Feshitan,et al. Microbubble size isolation by differential centrifugation. , 2009, Journal of colloid and interface science.
[2] Elisa E. Konofagou,et al. Dependence of the reversibility of focused- ultrasound-induced blood-brain barrier opening on pressure and pulse length in vivo , 2013, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control.
[3] N. McDannold,et al. Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[4] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[5] K. Hynynen,et al. Ultrasound Enhanced Delivery of Molecular Imaging and Therapeutic Agents in Alzheimer's Disease Mouse Models , 2008, PloS one.
[6] James J. Choi,et al. Activation of signaling pathways following localized delivery of systemically administered neurotrophic factors across the blood–brain barrier using focused ultrasound and microbubbles , 2012, Physics in medicine and biology.
[7] G. Gerhardt,et al. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. , 2005, Journal of neurosurgery.
[8] Kullervo Hynynen,et al. Targeted Delivery of Neural Stem Cells to the Brain Using MRI-Guided Focused Ultrasound to Disrupt the Blood-Brain Barrier , 2011, PloS one.
[9] T. Yen,et al. Noninvasive and Targeted Gene Delivery into the Brain Using Microbubble-Facilitated Focused Ultrasound , 2013, PloS one.
[10] B. Hoffer,et al. Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.
[11] A. Björklund,et al. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle , 1999, The European journal of neuroscience.
[12] Yao-Sheng Tung,et al. A quantitative pressure and microbubble‐size dependence study of focused ultrasound‐induced blood‐brain barrier opening reversibility in vivo using MRI , 2012, Magnetic resonance in medicine.
[13] J. Jankovic,et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD , 2003, Neurology.
[14] G. Gerhardt,et al. Intraputamenal Infusion of Exogenous Neurturin Protein Restores Motor and Dopaminergic Function in the Globus Pallidus of MPTP-Lesioned Rhesus Monkeys , 2008, Cell transplantation.
[15] J. Bloch,et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.
[16] D. Brooks,et al. Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.
[17] G. Gerhardt,et al. Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys , 2002, Neurobiology of Aging.
[18] Mu-Yi Hua,et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. , 2010, Radiology.
[19] Yau-Yau Wai,et al. Hemorrhage detection during focused-ultrasound induced blood-brain-barrier opening by using susceptibility-weighted magnetic resonance imaging. , 2008, Ultrasound in medicine & biology.
[20] Yi Ai,et al. Trophic factor distribution predicts functional recovery in parkinsonian monkeys , 2005, Annals of neurology.
[21] Mark Stacy,et al. Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease , 2006, Annals of neurology.
[22] Mickael Tanter,et al. Dynamic Study of Blood–Brain Barrier Closure after its Disruption using Ultrasound: A Quantitative Analysis , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[23] W. Pardridge. The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.
[24] T. Itakura,et al. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson’s disease , 2002, Brain Research.
[25] Win-Li Lin,et al. Quantitative evaluation of focused ultrasound with a contrast agent on blood-brain barrier disruption. , 2007, Ultrasound in medicine & biology.
[26] V. Ferrera,et al. Noninvasive, Transient and Selective Blood-Brain Barrier Opening in Non-Human Primates In Vivo , 2011, PloS one.
[27] James J. Choi,et al. Noninvasive, transcranial and localized opening of the blood-brain barrier using focused ultrasound in mice. , 2007, Ultrasound in medicine & biology.
[28] E. Konofagou,et al. Permeability assessment of the focused ultrasound-induced blood–brain barrier opening using dynamic contrast-enhanced MRI , 2010, Physics in medicine and biology.
[29] Jie Shi,et al. Targeted Delivery of GDNF through the Blood–Brain Barrier by MRI-Guided Focused Ultrasound , 2012, PloS one.
[30] Mark Borden,et al. Microbubble Compositions, Properties and Biomedical Applications. , 2009, Bubble science engineering and technology.
[31] Richard Grondin,et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. , 2002, Brain : a journal of neurology.
[32] Natalia Vykhodtseva,et al. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI‐guided focused ultrasound , 2007, International journal of cancer.
[33] A. Ruifrok,et al. Quantification of histochemical staining by color deconvolution. , 2001, Analytical and quantitative cytology and histology.
[34] K. Hynynen,et al. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. , 2001, Radiology.
[35] 木下 学. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption , 2007 .
[36] K. Bankiewicz,et al. Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain , 2010, Neuropharmacology.
[37] L. Rubin,et al. The cell biology of the blood-brain barrier. , 1999, Annual review of neuroscience.
[38] A. Lang,et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients , 2013, Neurology.
[39] S. Gill,et al. Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study , 2005, Annals of neurology.
[40] E. Mufson,et al. Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brains , 2011, Movement disorders : official journal of the Movement Disorder Society.
[41] R. Bakay,et al. Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys , 2006, Annals of neurology.
[42] M. Hennerici,et al. Focal delivery of AAV2/1-transgenes into the rat brain by localized ultrasound-induced BBB Opening. , 2014, Annals of neurosciences.
[43] P. Tofts,et al. Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.